Chemical
castration uses agonists and antagonists
as a prostate cancer hormone therapy. LHRH agonists
or GnRH agonists and LHRH antagonists or GnRH antagonists
ablate 90 to 95 percent of body’s testosterone
by interfering with the production process. Unlike surgical
castration, the effects of using agonist and antagonists
for prostate cancer are reversible. After a patient
discontinues hormone therapy, his body will begin to
produce testosterone once again.
|
